A decline in both revenues (more than 10% year-over-year) and EPS (also down 10%) is practically guaranteed to put investors off. What may help see Pfizer through is its future. The trailing 12-month price/earnings ratio is a large 23.68, while the future P/E ratio comes back to earth with a current print of 14.65.
The most recent analysts’ calls on the stock are also positive:
- Bernstein maintained its Outperform rating and boosted the price target from $38 to $39
- Jefferies initiated coverage in mid-June with an Overweight rating and a price target of $45
- Piper Jaffray initiated coverage in early June, also with an Overweight rating and $45 price target
Pfizer shares were recently trading at around $34.15 in the mid-afternoon on Monday. The consensus analyst price target is $38.25, and the 52-week range is $27.51 to $35.53. Pfizer has a 3.3% dividend yield, and its market cap is about $210.4 billion.The company has been in a state of flux following the the Zoetis spin-off and the pending Hospira acquisition. Analysts appear to believe that the $15 billion Hospira deal will give Pfizer a shot in the arm once the acquisition is final.
ALSO READ: 9 States with the Most Dangerous Weather
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
